Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)

Organon

Status: Completed

Conditions: Hypercholesterolemia

Treatments: Drug: statin; Drug: ezetimibe

Study type: Observational

Funder types: Industry

Identifiers

NCT00705081

P04276

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and tolerability of the low-density lipoprotein-cholesterol (LDL-C) lowering in an Indonesian population treated with ezetimibe co-administered with a statin in routine daily practice. In addition, the study will investigate whether and to what extent the target levels set by the participating doctors are achieved by the co-administration therapy.

Full description

Sampling method: invitation to the physician's patients.

Enrollment: 453 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All subjects that were to receive ezetimibe 10 mg as prescribed in daily practice

Exclusion criteria

• N/A

Trial design

453 participants in 2 patient groups

Not previously treated

Description:

subjects with hypercholesterolemia, who had never been treated with any cholesterol-lowering agent, and received the combination of ezetimibe 10 mg and a statin as initiation therapy

Treatment:

Drug: ezetimibe

Drug: statin

Previously treated with statin

Description:

subjects with hypercholesterolemia, who were previously treated with a statin, and received ezetimibe 10 mg as add-on therapy

Treatment:

Drug: ezetimibe

Drug: statin